This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.
Note: We can assist only if the medicine is unavailable in your country.”
Besremi (ropeginterferon alfa-2b)
General Description:
Besremi (ropeginterferon alfa-2b) is a long-acting interferon therapy used for the treatment of Polycythaemia Vera (PV) in adult patients.
It works by modulating the immune system to reduce excessive red blood cell production and control hematocrit levels in patients with PV. As a pegylated form of interferon alfa-2b, Besremi offers prolonged activity, allowing for less frequent dosing compared to conventional interferons while maintaining effective disease control.
Disease Indications:
Polycythaemia Vera (PV)
Manufacturer:
AOP Orphan Pharmaceuticals
Usage:
Subcutaneous
Medicine Approved by:
• European Medicines Agency (EMA)
• Food and Drug Administration (FDA)
• Pharmaceuticals and Medical Devices Agency (PMDA, Japan)
Package:
• 1 pre-filled pen × 250 mcg/0.5 mL
• 3 pre-filled pens × 250 mcg/0.5 mL
Shipping:
Cold Chain Shipping
Besremi contains biologic ingredients that are sensitive to heat, light, and handling. To preserve product stability and efficacy, it is transported under cold chain shipping conditions, using specialized medical couriers equipped with temperature-controlled boxes and vehicles.
Although cold chain shipping may be more costly than standard delivery, it ensures that Besremi remains uncompromised, safe, and fully effective upon arrival.
How to Access Besremi (ropeginterferon alfa-2b) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?
If Besremi (ropeginterferon alfa-2b) is not yet approved or commercially available in India, MitoGENE can assist patients and healthcare providers in legally obtaining it through the Named Patient Program (NPP).
Here’s how the process works:
